{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:54:06Z","timestamp":1769640846912,"version":"3.49.0"},"reference-count":25,"publisher":"Rambam Health Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>The evolving landscape of metastatic prostate cancer (mPCa) necessitates a redefinition of the urologist\u2019s role, extending beyond diagnosis to active participation in therapeutic and surgical management. This review outlines evidence-based approaches to biopsy and surgical interventions across the disease spectrum. Prostate biopsy remains fundamental for diagnosis, treatment stratification, and molecular profiling, with targeted and metastatic lesion sampling improving precision oncology. For symptom relief, surgical management of bladder outlet obstruction through transurethral resection of the prostate and holmium laser enucleation of the prostate remains essential, with emerging data suggesting possible oncologic benefits when combined with systemic therapy. GreenLight photoselective vaporization may represent an alternative option, though evidence remains limited. Cytoreductive radical prostatectomy in carefully selected patients with metastatic hormone-sensitive disease may provide improved local control and delayed progression, supported by growing biological rationale but constrained by the retrospective nature of current evidence. Collectively, these findings underscore the expanding multidisciplinary role of the urologist in mPCa care, emphasizing the need for prospective studies to validate the integration of surgical approaches within systemic treatment frameworks.<\/jats:p>","DOI":"10.5041\/rmmj.10564","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:17:48Z","timestamp":1769599068000},"page":"e0003","source":"Crossref","is-referenced-by-count":0,"title":["The Expanding Role of the Urologist in Metastatic Prostate Cancer: From Biopsy to Surgical Interventions"],"prefix":"10.5041","volume":"17","author":[{"name":"The Department of Urology, Rambam Health Care Campus, Haifa, Israel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-5415","authenticated-orcid":false,"given":"Nicola","family":"Fazaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etan","family":"Eigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Department of Urology, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameer","family":"Nsair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Department of Urology, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Department of Urology, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilad","family":"Amiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Department of Urology, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azik","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Department of Urology, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2983","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref0","unstructured":"1. World Cancer Research Fund. Prostate cancer statistics. 2025. Available at: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/prostate-cancer-statistics\/ (accessed December 9, 2025)."},{"key":"ref1","unstructured":"2. American Cancer Society. Cancer Facts & Figures 2025. Atlanta, GA, USA: American Cancer Society; 2025. Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf (accessed December 9, 2025)."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","article-title":"Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States","volume":"4","author":"Kelly","year":"2018","unstructured":"3. Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 2018;4:121-7.","journal-title":"Eur Urol Focus"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s11255-023-03531-2","article-title":"Is systematic prostate biopsy an overkill in metastatic prostate carcinoma? A prospective validation","volume":"55","author":"Sureka","year":"2023","unstructured":"4. Sureka SK, Misra A, Raj H, Shukla A, Singh UP. Is systematic prostate biopsy an overkill in metastatic prostate carcinoma? A prospective validation. Int Urol Nephrol 2023;55:1133-7.","journal-title":"Int Urol Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1200\/EDBK_175510","article-title":"Personalizing therapy for metastatic prostate cancer: the role of solid and liquid tumor biopsies","volume":"37","author":"Friedlander","year":"2017","unstructured":"5. Friedlander TW, Pritchard CC, Beltran H. Personalizing therapy for metastatic prostate cancer: the role of solid and liquid tumor biopsies. Am Soc Clin Oncol Educ Book 2017;37:358-69.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cncr.31173","article-title":"Bone biopsy protocol for advanced prostate cancer in the era of precision medicine","volume":"124","author":"Sailer","year":"2018","unstructured":"6. Sailer V, Schiffman MH, Kossai M, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer 2018;124:1008-15.","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11934-024-01229-1","article-title":"The role of transurethral bph surgeries in management of urinary symptoms in prostate cancer patients, narrative review","volume":"26","author":"Elsaqa","year":"2025","unstructured":"7. Elsaqa M, El Tayeb MM. The role of transurethral bph surgeries in management of urinary symptoms in prostate cancer patients, narrative review. Curr Urol Rep 2025;26:7.","journal-title":"Curr Urol Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/01.ju.0000104845.24632.92","article-title":"Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer","volume":"171","author":"Crain","year":"2004","unstructured":"8. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 2004;171:668-71.","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1089\/end.2019.0108","article-title":"Palliative transurethral resection of the prostate in patients with metastatic prostate cancer: a prospective study of 188 patients","volume":"33","author":"Qu","year":"2019","unstructured":"9. Qu M, Zhu F, Chen H, et al. Palliative transurethral resection of the prostate in patients with metastatic prostate cancer: a prospective study of 188 patients. J Endourol 2019;33:570-5.","journal-title":"J Endourol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10103-019-02913-2","article-title":"Efficacy and outcome of holmium laser enucleation of prostate in patients with urinary retention due to advanced prostate cancer","volume":"35","author":"Tang","year":"2020","unstructured":"10. Tang M, Wang C, Li P, Zhang Q, Qian J, Meng X. Efficacy and outcome of holmium laser enucleation of prostate in patients with urinary retention due to advanced prostate cancer. Lasers Med Sci 2020;35: 1307-13.","journal-title":"Lasers Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/j.1464-410X.2010.09356.x","article-title":"The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer","volume":"106","author":"Krupski","year":"2010","unstructured":"11. Krupski TL, Stukenborg GJ, Moon K, Theodorescu D. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int 2010;106:1477-83.","journal-title":"BJU Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"726534","DOI":"10.3389\/fsurg.2021.726534","article-title":"The impact of palliative transurethral resection of the prostate on the prognosis of patients with bladder outlet obstruction and metastatic prostate cancer: a population-matched study","volume":"8","author":"Fang","year":"2021","unstructured":"12. Fang K, Song P, Zhang J, et al. The impact of palliative transurethral resection of the prostate on the prognosis of patients with bladder outlet obstruction and metastatic prostate cancer: a population-matched study. Front Surg 2021;8:726534.","journal-title":"Front Surg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00432-018-2597-5","article-title":"Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study","volume":"144","author":"Choi","year":"2018","unstructured":"13. Choi SY, Ryu J, You D, et al. Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study. J Cancer Res Clin Oncol 2018; 144:751-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s10103-012-1252-7","article-title":"GreenLight HPS 120-W laser photoselective vaporization of the prostate as early therapy for acute urinary retention in advanced prostate cancer patients","volume":"28","author":"Chen","year":"2013","unstructured":"14. Chen D, Xue B, Shan Y, Yang D, Sun C, Gao J. GreenLight HPS 120-W laser photoselective vaporization of the prostate as early therapy for acute urinary retention in advanced prostate cancer patients. Lasers Med Sci 2013;28:1339-44.","journal-title":"Lasers Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.5534\/wjmh.240060","article-title":"Holmium laser enucleation of the prostate for advanced prostate cancer-related bladder outlet obstruction: assessing effectiveness and unraveling factors impacting postoperative urinary incontinence","volume":"42","author":"Kim","year":"2024","unstructured":"15. Kim HW, Lee JZ, Kim TN, Shin DG. Holmium laser enucleation of the prostate for advanced prostate cancer-related bladder outlet obstruction: assessing effectiveness and unraveling factors impacting postoperative urinary incontinence. World J Mens Health 2024;42:650-7.","journal-title":"World J Mens Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.urology.2017.02.051","article-title":"Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective Local Treatment of Metastatic Prostate Cancer (LoMP) trial","volume":"106","author":"Poelaert","year":"2017","unstructured":"16. Poelaert F, Verbaeys C, Rappe B, et al. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective Local Treatment of Metastatic Prostate Cancer (LoMP) trial. Urology 2017;106:146-52.","journal-title":"Urology"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Gonz\u00e1lez-Browne C, D\u00edaz J, Pinto I, et al. Cytoreductive radical prostatectomy versus no local treatment in patients with metastatic prostate cancer. Medwave 2023;23.","DOI":"10.5867\/medwave.2023.04.2661"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","article-title":"Diagnosis and treatment of ovarian cancer","volume":"32","author":"Orr","year":"2018","unstructured":"18. Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am 2018;32: 943-64.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2015.06.004","article-title":"Treatment of the prostate in the presence of metastases: lessons from other solid tumors","volume":"69","author":"AI","year":"2016","unstructured":"19. Neugut AI, Gelmann EP. Treatment of the prostate in the presence of metastases: lessons from other solid tumors. Eur Urol 2016;69:795-6.","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.soc.2018.02.012","article-title":"Patient selection for cytoreductive surgery","volume":"27","author":"Grotz","year":"2018","unstructured":"20. Grotz TE, Fournier KF, Mansfield PF. Patient selection for cytoreductive surgery. Surg Oncol Clin N Am 2018;27:443-62.","journal-title":"Surg Oncol Clin N Am"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4111\/icu.2018.59.1.2","article-title":"Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis","volume":"59","author":"Garc\u00eda-Perdomo","year":"2018","unstructured":"21. Garc\u00eda-Perdomo HA, Zapata-Copete JA, Castillo-Cobaleda DF. Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis. Investig Clin Urol 2018;59:2-9.","journal-title":"Investig Clin Urol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2025.43.5_suppl.157","article-title":"The role of cytoreductive radical prostatectomy in the management of patients with metastatic hormone-sensitive prostate cancer","volume":"43","author":"Heidenreich","year":"2025","unstructured":"22. Heidenreich A, Pfister D, Paffenholz P, Rieger C, Weiten R. The role of cytoreductive radical prostatectomy in the management of patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2025;43:157.","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.euo.2024.06.010","article-title":"Patients' preferences for cytoreductive treatments in newly diagnosed metastatic prostate cancer: the IP5-MATTER study","volume":"8","author":"Connor","year":"2025","unstructured":"23. Connor MJ, Genie M, Dudderidge T, et al. Patients' preferences for cytoreductive treatments in newly diagnosed metastatic prostate cancer: the IP5-MATTER study. Eur Urol Oncol 2025;8:663-73.","journal-title":"Eur Urol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"15330338231216012","DOI":"10.1177\/15330338231216011","article-title":"Current controversy and developments regarding the cytoreductive prostatectomy for oligometastatic prostate cancer","volume":"22","author":"Tian","year":"2023","unstructured":"24. Tian Y, Mao Y, Tang Z, Hu M. Current controversy and developments regarding the cytoreductive prostatectomy for oligometastatic prostate cancer. Technol Cancer Res Treat 2023;22:15330338231216012.","journal-title":"Technol Cancer Res Treat"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study","volume":"193","author":"Heidenreich","year":"2015","unstructured":"25. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015;193:832-8.","journal-title":"J Urol"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/3500\/2\/PublishFiles\/4080Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:30:55Z","timestamp":1769599855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/69\/articles\/4080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,28]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10564","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}